Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design.

Von Kreudenstein TS, Escobar-Carbrera E, Lario PI, D'Angelo I, Brault K, Kelly J, Durocher Y, Baardsnes J, Woods RJ, Xie MH, Girod PA, Suits MD, Boulanger MJ, Poon DK, Ng GY, Dixit SB.

MAbs. 2013 Sep-Oct;5(5):646-54. doi: 10.4161/mabs.25632. Epub 2013 Jul 8.

2.

Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.

Muda M, Gross AW, Dawson JP, He C, Kurosawa E, Schweickhardt R, Dugas M, Soloviev M, Bernhardt A, Fischer D, Wesolowski JS, Kelton C, Neuteboom B, Hock B.

Protein Eng Des Sel. 2011 May;24(5):447-54. doi: 10.1093/protein/gzq123.

PMID:
21498564
3.

A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens.

Moore GL, Bautista C, Pong E, Nguyen DH, Jacinto J, Eivazi A, Muchhal US, Karki S, Chu SY, Lazar GA.

MAbs. 2011 Nov-Dec;3(6):546-57. doi: 10.4161/mabs.3.6.18123. Epub 2011 Nov 1.

4.

Antibody therapeutics, antibody engineering, and the merits of protein stability.

Demarest SJ, Glaser SM.

Curr Opin Drug Discov Devel. 2008 Sep;11(5):675-87. Review.

PMID:
18729019
5.

Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.

Gu J, Ghayur T.

Methods Enzymol. 2012;502:25-41. doi: 10.1016/B978-0-12-416039-2.00002-1.

PMID:
22208980
6.
7.

SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.

Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo KM, Huston JS.

Protein Eng Des Sel. 2010 Apr;23(4):195-202. doi: 10.1093/protein/gzp094. Epub 2010 Feb 4.

PMID:
20299542
8.

A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and Met exhibits potent antitumor activity.

Choi HJ, Kim YJ, Lee S, Kim YS.

Mol Cancer Ther. 2013 Dec;12(12):2748-59. doi: 10.1158/1535-7163.MCT-13-0628. Epub 2013 Oct 16.

9.

Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.

Strop P, Ho WH, Boustany LM, Abdiche YN, Lindquist KC, Farias SE, Rickert M, Appah CT, Pascua E, Radcliffe T, Sutton J, Chaparro-Riggers J, Chen W, Casas MG, Chin SM, Wong OK, Liu SH, Vergara G, Shelton D, Rajpal A, Pons J.

J Mol Biol. 2012 Jul 13;420(3):204-19. doi: 10.1016/j.jmb.2012.04.020. Epub 2012 Apr 25.

PMID:
22543237
10.

Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.

Vincent KJ, Zurini M.

Biotechnol J. 2012 Dec;7(12):1444-50. doi: 10.1002/biot.201200250. Epub 2012 Nov 1. Review.

PMID:
23125076
11.

Antiparallel conformation of knob and hole aglycosylated half-antibody homodimers is mediated by a CH2-CH3 hydrophobic interaction.

Elliott JM, Ultsch M, Lee J, Tong R, Takeda K, Spiess C, Eigenbrot C, Scheer JM.

J Mol Biol. 2014 May 1;426(9):1947-57. doi: 10.1016/j.jmb.2014.02.015. Epub 2014 Feb 24.

PMID:
24576605
12.

Protein engineering and the use of molecular modeling and simulation: the case of heterodimeric Fc engineering.

Spreter Von Kreudenstein T, Lario PI, Dixit SB.

Methods. 2014 Jan 1;65(1):77-94. doi: 10.1016/j.ymeth.2013.10.016. Epub 2013 Nov 6.

PMID:
24211748
13.

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.

Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, van Berkel PH, van de Winkel JG, Schuurman J, Parren PW.

Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5145-50. doi: 10.1073/pnas.1220145110. Epub 2013 Mar 11.

14.

Structural understanding of stabilization patterns in engineered bispecific Ig-like antibody molecules.

Jordan JL, Arndt JW, Hanf K, Li G, Hall J, Demarest S, Huang F, Wu X, Miller B, Glaser S, Fernandez EJ, Wang D, Lugovskoy A.

Proteins. 2009 Dec;77(4):832-41. doi: 10.1002/prot.22502.

PMID:
19626705
15.

LC-MS characterization and purity assessment of a prototype bispecific antibody.

Woods RJ, Xie MH, Von Kreudenstein TS, Ng GY, Dixit SB.

MAbs. 2013 Sep-Oct;5(5):711-22. doi: 10.4161/mabs.25488. Epub 2013 Jun 24.

16.

Rapid optimization and prototyping for therapeutic antibody-like molecules.

Xu L, Kohli N, Rennard R, Jiao Y, Razlog M, Zhang K, Baum J, Johnson B, Tang J, Schoeberl B, Fitzgerald J, Nielsen U, Lugovskoy AA.

MAbs. 2013 Mar-Apr;5(2):237-54. doi: 10.4161/mabs.23363. Epub 2013 Feb 7.

17.

Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.

Klein C, Sustmann C, Thomas M, Stubenrauch K, Croasdale R, Schanzer J, Brinkmann U, Kettenberger H, Regula JT, Schaefer W.

MAbs. 2012 Nov-Dec;4(6):653-63. doi: 10.4161/mabs.21379. Epub 2012 Aug 27. Review.

18.

A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis.

Xie Z, Guo N, Yu M, Hu M, Shen B.

J Immunol Methods. 2005 Jan;296(1-2):95-101. Epub 2004 Nov 19.

PMID:
15680154
19.

Application of the Fc fusion format to generate tag-free bi-specific diabodies.

Asano R, Ikoma K, Kawaguchi H, Ishiyama Y, Nakanishi T, Umetsu M, Hayashi H, Katayose Y, Unno M, Kudo T, Kumagai I.

FEBS J. 2010 Jan;277(2):477-87. doi: 10.1111/j.1742-4658.2009.07499.x. Epub 2009 Dec 15.

20.

Engineered IgG1-Fc--one fragment to bind them all.

Lobner E, Traxlmayr MW, Obinger C, Hasenhindl C.

Immunol Rev. 2016 Mar;270(1):113-31. doi: 10.1111/imr.12385. Review.

Supplemental Content

Support Center